Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
TherOx raises $30 million: Privately held developer of the DownStream SuperSaturated Oxygen Therapy system for adjunctive treatment of acute myocardial infarction raises $30 million from DAG Ventures and other investors. A PMA application for the device is pending. Downstream is designed to reduce infarct size and preserve heart muscle after a severe heart attack by super oxygenating a patient's blood for direct re-infusion to oxygen deficient tissue after a patient has already been treated with balloon angioplasty and a stent. Based in Irvine, Calif., the firm reported results last October from its pivotal, 300-patient AMIHOT II trial, including a statistically significant 6.5% reduction in infarct size using the device. Other potential applications for the technology include ischemic stroke, cancer and wound healing, according to the company (1"The Gray Sheet" Dec. 3, 2007, p. 15)
You may also be interested in...
Four Firms Apply For Medicare New-Tech Add-On Payments
Four manufacturers are seeking new-technology payments for their devices in the fiscal year 2009 inpatient payment rule, despite industry's frustration with CMS' process for granting the add-on payments
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.